PHC Holdings Appoints John Marotta as President and CEO
Tokyo, November 25, 2020 - PHC Holdings Corporation (headquarters: Minato-ku Tokyo, Japan, hereafter PHCHD) has today announced that they have appointed John Marotta as President and CEO of PHCHD, effective December 1, 2020. John succeeds Michael Kloss, who has been appointed as Chairman of PHCHD.
John joined PHCHD earlier this year in July 2020, when he was appointed President of Epredia, the anatomical pathology business that was acquired from Thermo Fisher in 2019. In the short time since his arrival, he has already been creating significant value both at Epredia and across the PHC Group through efficiencies, integration and process improvement.
With more than 20 years in the medtech and diagnostics industries, John has extensive experience in medical device operations, transformation and integration. Prior to joining PHCHD, John was a Senior Vice President at Envista Holdings (a dental spin-out from Danaher) leading six global functions. In this role, he oversaw these functions in preparation for the IPO of Envista, led initiatives to drive growth, operational efficiency and integration, and was responsible for the deployment of the Envista Business System (from the Danaher Business System). John has also held various positions in medtech and diagnostics companies including Danaher, Cardinal Health, Synthes and Johnson & Johnson.
As the President and CEO, John will be responsible for overall leadership and direction of the PHC Group. As Chairman, Michael will move into an advisory role, providing senior strategic input as a member of the Board of Directors, through the end of March 2021.
Michael Kloss, explained, “We are entering a new phase for the PHC Group, which will have a greater focus on integration, execution and the expansion of our business in Life Sciences and Diagnostics. I believe that John’s integration experience and operational expertise in the medtech industry will prove to be invaluable, enabling him to successfully lead the company through this next phase. He has my full support and I look forward to working with him over the coming months to enable the PHC Group to reach the next level of growth and expansion.”
Hiro Hirano, Chairman of the Nomination Committee of PHCHD and CEO of KKR Japan, added, “Due to his strong experience in the medtech and diagnostic sectors, alongside his proven track record in integration and value creation, we believe John is the right person to successfully lead the PHC Group to further growth. The Board of Directors would like to thank Michael for his strong leadership and strategic vision over the last two years as we continue to transform the PHC Group. The progress we have made during this time puts the company in a strong position as it now embarks on its next phase.”
John Marotta said, “I am excited to be taking over at the President and CEO of PHCHD. We have a world-class portfolio of innovative solutions in various sectors of healthcare and highly talented employees across the world. I look forward to working with them to successfully grow our business. Our next priority will be accelerating the integration of the businesses we have acquired and executing on our growth strategies. Our ambition is to be the leading provider of best-in-class precision solutions in Diagnostics and Life Sciences globally, and Integrated Healthcare Solutions in Japan, and I believe we have the right strategy to achieve this together.”
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with subsidiaries including PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, and LSI Medience Corporation. Committed to its corporate mission, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company develops, manufactures and sells solutions across diabetes management, diagnostics, life sciences and integrated healthcare. The PHC Group’s consolidated net sales in FY2019 were 272.6 billion yen with global distribution of products and services in more than 125 countries.